USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
2015 Global Survey on Liquid Biopsy Adoption Trends
2015 Global Survey on Liquid Biopsy Adoption Trends
Learn the Promising Technologies and Bottlenecks for CTCs and ctDNA—A Voice of Customer Study
04-Nov-2015
North America
Description
The primary goal of this research is to analyze the current and future adoption patterns on the usage of liquid biopsy. Key information the survey seeks to collect include the following:
• Current and future use of liquid biopsy by organization type
• Timeframe of liquid biopsy adoption amidst future users
• Predominantly used cell types—CTCs, ctDNA, cfDNA and Evs—by organization type
• Sample inflow to conduct liquid biopsy tests
• Preference for sample types: blood, saliva, stool, serum, and so on.
• Correlation analysis of sample type and biomarker type
• Promising applications for liquid biopsy—current and future
• Predominant approaches to liquid biopsy: hotspot panels, single marker tests, and so on
• Technologies used to detect CtDNA—current vs. future users
• Technologies used to detect CTCs
• Vendor popularity for specific biomarkers and reimbursement scenario
• Bottlenecks to mainstream implementation of liquid biopsy
Table of Contents
Research Objectives
Research Methodology
Research Methodology (continued)
Respondent Demographics
Respondent Demographics (continued)
Respondent Demographics—Current and Future Users
Key Findings
Top 7 Brands for Liquid Biopsy
Overall Use of Liquid Biopsy by Organization Type
Timeframe for Future Adoption
Timeframe for Adoption by Organization Type
Opinion on Use of Liquid Biopsy as an Adjunct to Tissue Biopsy
Liquid Biopsy as an Adjunct to Tissue Biopsy (continued)
Overall Biomarker Usage
Overall Biomarker Usage—Hospital Laboratories
Overall Biomarker Usage—Pharmaceutical and Diagnostic Companies
Overall Biomarker Usage—Reference Laboratories*
Overall Biomarker Usage—Research Institutes and Universities
Sample Volume Per Month
Sample Format—Overall
Sample Format—Current Users vs. Future Users
Sample Format by Organization Type
Technologies Used to Detect ctDNA—Overview
Technologies Used to Detect ctDNA—Current and Future User Trends
Technologies Used to Detect ctDNA by Organization Type
Technologies Used to Detect CTC—Overview
Technologies Used to Detect CTC—Current and Future User Trends
Technologies Used to Detect CTC by Organization Type
Brand Familiarity for Tumor Profiling
Promising Applications of Liquid Biopsy (Overall)
Promising Applications by Organization Type
Promising Applications—Current and Future Users
Bottlenecks in Liquid Biopsy
Bottlenecks by Biomarker Type
Liquid Biopsy Usage to Profile Types
Tumor Profiling by Organization Type
Liquid Biopsy Approaches—Current vs. Future Users
Liquid Biopsy Approach by Organization Type
Correlation of Sample Type and Liquid Biopsy Approach
CTC-Specific Liquid Biopsy Approaches—Current vs. Future Users
ctDNA-Specific Liquid Biopsy Approaches—Current vs. Future Users
Germline or cfDNA-Specific Liquid Biopsy Approaches—Current vs. Future Users
EVs-Specific Liquid Biopsy Approaches—Current vs. Future Users
Overall Brand Perception
Brand Perception Organization Type
Top 7 Current and Future Brand Perception
Brand Preference by Biomarker Type—CTCs
Brand Preference by Biomarker Type—CtDNA
Brand Preference by Biomarker Type—Germline and cfDNA
Brand Preference by Biomarker Type—Evs
Reimbursement Trends (Overall)
Reimbursement Trend by Organization Type
Reimbursement by Technology—ctDNA
Reimbursement by Technology—CTC
Mutant Allele Detection Limit—Diagnosis and Monitoring
Reasons for Choosing Blood Over Other Sample Types
Reasons for Choosing Blood Over Other Sample Types (continued)
Reasons for Choosing Blood Over Other Sample Types (continued)
Reasons for Choosing Blood Over Other Sample Types (continued)
Reasons for Choosing Blood Over Other Sample Types (continued)
Legal Disclaimer
Additional Sources of Information
The Frost & Sullivan Story
Value Proposition—Future of Your Company & Career
North America and Europe Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Our Blue Ocean Strategy
Popular Topics
| No Index | No |
|---|---|
| Podcast | No |
| Author | Divyaa Ravishankar |
| WIP Number | 9AB9-00-2F-00-00 |
| Is Prebook | No |